NCT01717300View on ClinicalTrials.gov

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)

PHASE3CompletedINTERVENTIONAL
Enrollment

459

Participants

Timeline

Start Date

November 6, 2012

Primary Completion Date

October 29, 2014

Study Completion Date

October 29, 2014

Conditions
Hypercholesterolemia
Interventions
DRUG

Anacetrapib 100 mg

100 mg tablet, oral, once daily for 24 weeks

DRUG

Placebo for anacetrapib 100 mg

Placebo tablet, orally, once daily for 24 weeks

DRUG

Anacetrapib 25 mg

25 mg tablet, oral, once daily for 24 weeks

DRUG

Placebo for anacetrapib 25 mg

Placebo tablet, orally, once daily for 24 weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01717300 - A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021) | Biotech Hunter | Biotech Hunter